H.C. Wainwright upgraded Lyell Immunopharma (LYEL) to Buy from Neutral with a price target of $45, up from $20. The firm has “increased conviction” following the company’s recent data and a key opinion leader call on colorectal cancer. Ronde-cel has established itself as the “durability leader in the CD19/CD20 CAR-T race,” the analyst tells investors in a research note. H.C. Wainwright adds that its new expert feedback confirms that Lyell’s existing LYL273 dataset is “already clearing the clinical high jump for success” in third and fourth lines colorectal cancer “by a wide margin.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYEL:
- Lyell Immunopharma Presents Promising CAR T-Cell Data
- Lyell Immunopharma announces new data from trial of rondecabtagene autoleucel
- Lyell Immunopharma files to sell 1.9M shares of common stock for holders
- Lyell Immunopharma Modernizes Bylaws for Shareholder Engagement
- Lyell Immunopharma price target raised to $20 from $10 at H.C. Wainwright